An importance of identification of double variant methylenetetrahydrofolate reductase gene C677T and A1298C in cis configuration for pharmacogenetic studies.
aDepartment of Advanced Biotechnologies and Bioimaging, Laboratory of Molecular Diagnostics bDepartment of Advanced Biotechnologies and Bioimaging, Laboratory of Thrombosis and Hemostasis, IRCCS San Raffaele Pisana, Rome, Italy cDepartment of Neurology, Miller School of Medicine, University of Miami, Miami, Florida, USA dMedical Oncology Unit, Tor Vergata Clinical Center, University of Rome eInterinstitutional Multidisciplinary BioBank (BioBIM), Department of Advanced Biotechnologies and Bioimaging, IRCCS San Raffaele Pisana, Rome, Italy.
Raffaele
R
Palmirotta
Barbara
B
Leone
Maria Laura
ML
De Marchis
Giorgia
G
Ludovici
Annalisa
A
Savonarola
Patrizia
P
Ferroni
Tatjana
T
Rundek
Mario
M
Roselli
David
D
Della-Morte
Fiorella
F
Guadagni
D005260:Female; D005493:Folic Acid Antagonists / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects*; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics*
D005493:Folic Acid Antagonists; D042965:Methylenetetrahydrofolate Reductase (NADPH2); D008727:Methotrexate